Summary
In the present experiments, it was shown that the catalepsy induced by the dopamine D1 antagonist SCH 23390 (0.2 mgkg−1 sc), was completely antagonised by the administration of 8-OH-DPAT (0.1 mg kg−1 sc) for the duration of the effect of SCH 23390 (approx. 120 min). Neither the catalepsy induced by raclopride (16 mg kg−1 sc) nor that induced by SCH 23390 (0.2 mg kg−1 sc) could be antagonised by treatment with the 5-HT2 receptor antagonist ritanserin (0.13–2.0 mg kg−1 sc). Administration of SCH 23390 (0.0125–0.2 mg kg−1 sc) produced a significant suppression of avoidance behavior at all doses, and also produced a significant decrease in the number of intertriai crosses. At the higher doses, 0.05 and 0.2 mg kg−1 sc, there were also escape failures. In contrast to the finding in our previous report that raclopride and 8-OH-DPAT in a synergistic manner produce a suppression of conditioned avoidance behavior, no such interaction was found between 8-OH-DPAT (0.1 mg kg−1 sc) and SCH 23390 (6 μg kg−1 sc) in the present study.
Similar content being viewed by others
References
Ahlenius S (1991) Pharmacological evaluation of new antipsychotic drugs. In: Willner P (ed) Behavioral models in psychopharmacology. Cambridge University Press, Cambridge, pp 311–330
Ahlenius S, Hillegaart V (1986) Involvement of extrapyramidal motor mechanisms in the suppression of locomotor activity by antipsychotic drugs: a comparison between the effects produced by pre- and postsynaptic inhibition of dopaminergic neurotransmission. Pharmacol Biochem Behav 24: 1409–1415
Ahlenius, Ericson EL, Högberg K, Wijkström A (1991) Behavioral and biochemical effects of subchronic treatment with raclopride in the rat: tolerance and brain monoamine receptor sensitivity. Pharmacol Toxicol 68: 302–309
Baldessarini RJ (1990) Drugs and the treatment of psychiatric disorders. In: Goodman LS, Gilman A (eds) The pharmacological basis of therapeutics. Pergamon Press, New York, pp 383–435
Broekkamp CLE, Oosterloo SK, Berendsen HHG, van Delft AML (1988) Effect of metergoline, fenfluramine, and 8-OH-DPAT on catalepsy induced by haloperidol or morphine. Naunyn-Schmiedebergs Arch Pharmacol 338: 191–195
Christensen AV, Arnt J, Hyttel J, Larsen J-J, Svendsen O (1984) Pharmacological effects of a specific dopamine D-1 antagonist SCH 23390 in comparison with neuroleptics. Life Sci 34: 1529–1540
Clark D, White FJ (1987) D1 dopamine receptor-the search for function: critical evaluation of the D1-D2 dopamine receptor classification and its functional implications. Synapse 1: 347–388
Courvoisier S (1956) Pharmacodynamic basis for the use of chlorpromazine in psychiatry. J Clin Exp Psychopathol Q Rev Psychiatr Neurol 17: 25–37
Deutch AY, Moghaddam B, Innis RB, Krystal JH, Aghajanian GK, Bunney BS, Charney DS (1991) Mechanisms of action of atypical antipsychotic drugs: implications for novel therapeutic strategies for schizophrenia. Schizophr Res 4: 121–156
Hicks PB (1990) The effect of serotonergic agents on haloperidol-induced catalepsy. Life Sci 47: 1609–1615
Hillegaart V, Ahlenius S (1987) Effects of raclopride on exploratory locomotor activity, treadmill locomotion, conditioned avoidance behavior and catalepsy in rats: behavioural profile comparisons between raclopride, haloperidol and preclamol. Pharmacol Toxicol 60: 350–354
Hillegaart V, Ahlenius S, Fowler ChJ, Magnusson O (1988) Increased duration of dopamine receptor antagonist-induced effects on both behavior and striatal dopamine turnover by repeated testing in rats. Pharmacol Toxicol 63: 114–117
Invernizzi RW, Cervo L, Samanin R (1988) 8-hydroxy-2-(di-n-propylamino)tetralin, a selective serotonin1A receptor agonist, blocks haloperidol-induced catalepsy by an action on raphe nuclei medianus and dorsalis. Neuropharmacology 27: 515–518
Iorio LC, Barnett A, Leitz FH, Houser VP, Korduba CA (1983) SCH 23390, a potential benzamide antipsychotic with unique interactions on dopaminergic systems. J Pharmacol Exp Ther 226: 462–468
Janssen PAJ, Niemegeers CJE, Awouters F, Schellekens KHL, Megens AAHP, Meert TF (1988) Pharmacology of risperidone (R 64766), a new antipsychotic with serotonin-S2 and dopamine-D2 antagonistic properties. J Pharmacol Exp Ther 244: 685–693
Juul Povlsen U, Noring U, Lund Laursen A, Korsgaard S, Gerlach J (1986) Effects of serotonergic and anticholinergic drugs in haloperidol-induced dystonia in cebus monkeys. Clin Neuropharmacol 9: 84–90
Korsgaard S, Gerlach J, Christensson E (1985) Behavioral aspects of serotonin-dopamine interaction in the monkey. Psychopharmacology 118: 245–252
Köhler C, Hall H, Ögren S-O, Gawell L (1985) Specific in vitro and in vivo binding of [3H]-raclopride. A potent substituted benzamide drug with high affinity for dopamine D2 receptors in the rat brain. Biochem Pharmacol 34: 2251–2259
Lappalainen J, Hietala J, Koulu M, Syvälahti E (1990) Neurochemical effects of chronic coadministration of ritanserin and haloperidol: comparison with clozapine effects. Eur J Pharmacol 190: 403–407
Leysen JE, Gommeren W, Van Gompel P, Wynants J, Janssen PFM, Laduron PM (1985) Receptor-binding properties in vitro and in vivo of ritanserin a very potent and long acting serotonin-S2 antagonist. Mol Pharmacol 27: 600–611
Li CC (1964) Introduction to experimental statistics. McGraw-Hill, New York, pp 207–226
Liebman JM, Gerhardt SC, Gerber R (1989) Effects of 5-HT1A agonists and 5-HT2 antagonists of haloperidol-induced dyskinesias in squirrel monkeys: no evidence for reciprocal 5-HT-dopamine interaction. Psychopharmacology 97: 456–461
McMillen BA (1985) Comparative chronic effects of buspirone or neuroleptics on rat brain dopaminergic neurotransmission. J Neural Transm 64: 1–12
McMillen BA, Williams HL (1990) Effects of chronic ipsapirone on rat brain monoaminergic receptors and responses to chronic antipsychotic treatment. Biogenic Amines 7: 569–575
McMillen BA, Scott SM, Davanzo EA (1988) Reversal of neuroleptic-induced catalepsy by novel aryl-piperazine anxiolytic drugs. J Pharm Pharmacol 40: 885–887
Meltzer HY (1991) Dopaminergic and serotonergic mechanisms in the action of clozapine. In: Tamminga CA, Schultz SC (eds) Advances in Neuropsychiatry and Psychopharmacology, vol. 1 (Schizophrenia Res). Raven Press, New York, pp 333–338
Siegel S, Castellan Jr NJ (1988) Nonparametric statistics for the behavioral sciences. McGraw-Hill, New York
Tamminga CA, Gerlach J (1987) New neuroleptics and experimental antipsychotics in schizophrenia. In: Meltzer HY (ed) Psychopharmacology: the third generation of progress. Raven Press, New York, pp 1129–1140
Verhave T, Owen JE Jr, Robbins EB (1958) Effects of chlorpromazine and secobarbital on avoidance and escape behavior. Arch Int Pharmacol 116: 45–53
Wadenberg M-L, Ahlenius S (1988) Suppression of conditioned avoidance by 8-OH-DPAT in the rat. J Neural Transm 74: 195–198
Wadenberg M-L, Ahlenius S (1991) Antipsychotic-like profile of combined treatment with raclopride and 8-OH-DPAT in the rat: enhancement of antipsychotic-like effects without catalepsy. J Neural Transm [GenSect] 83: 43–53
Wadenberg M-L, Ahlenius S (1991) Effects of raclopride and haloperidol on spontaneous motor activity and on conditioned avoidance behavior in rats. Arzneimittelforschung 41: 692–695
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Wadenberg, M.L. Antagonism by 8-OH-DPAT, but not ritanserin, of catalepsy induced by SCH 23390 in the rat. J. Neural Transmission 89, 49–59 (1992). https://doi.org/10.1007/BF01245351
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01245351